Senti Biosciences
2 Corporate Drive, First Floor
South San Francisco
CA
94080
United States
Website: https://www.sentibio.com/
Email: info@sentibio.com
76 articles about Senti Biosciences
-
Senti Bio to Present at Chardan’s 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
4/18/2022
Senti Biosciences, Inc. (“Senti Bio”), a leading Gene Circuit company today announced that co-founders Tim Lu, MD, PhD, Chief Executive Officer, and Philip Lee, PhD, Chief Technology Officer, will participate in a Fireside Chat at Chardan’s 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on Monday, April 25, 2022 at 3:00 p.m. ET.
-
Senti Bio to Present Preclinical Data on Cancer-Killing Allogeneic CAR-NK Cells at AACR Annual Meeting
3/8/2022
Senti Bio, a leading gene circuit company, today announced the acceptance of an abstract for presentation at the American Association for Cancer Research (AACR) annual meeting in New Orleans taking place April 8–13, 2022.
-
Senti Bio to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference
1/6/2022
Senti Biosciences, Inc. (“Senti Bio”), a leading Gene Circuit company today announced that Tim Lu, MD, PhD, Chief Executive Officer and Co-Founder, will present a corporate overview at the 40th Annual J.P. Morgan Virtual Healthcare Conference on Tuesday, January 11, 2022 at 2:00 p.m. EST.
-
Senti Bio and Dynamics Special Purpose Corp. Announce Business Combination Agreement to Create Publicly Listed Company Pioneering Gene Circuit-Engineered Cell and Gene Therapies
12/20/2021
Senti Biosciences, Inc. and Dynamics Special Purpose Corp. today announced they have entered into a definitive business combination agreement to create a public company focused on Gene Circuit-engineered cell and gene therapies.
-
Senti Bio Highlights Preclinical Advances on Pipeline Candidate SENTI-202 at ASH 2021 Annual Meeting
12/13/2021
Senti Bio, a leading gene circuit company, announced new preclinical data from its gene circuit-engineered allogeneic CAR-NK cell therapy pipeline in a session yesterday at the American Society of Hematology (ASH) Annual Meeting and Exposition being held December 11–14.
-
Senti Bio to Present Preclinical Advances on Pipeline Candidate SENTI-202 at ASH 2021 Annual Meeting
11/4/2021
Senti Bio, a leading gene circuit company, announced that new preclinical data from its gene circuit-engineered allogeneic CAR-NK cell therapy pipeline will be presented at the 63rd American Society of Hematology Annual Meeting and Exposition being held December 11–14.
-
Senti Bio CEO Appointed to The Alliance for Regenerative Medicine 2022 Board of Directors
10/21/2021
Senti Bio, a leading gene circuit company, today announced that its co-founder and chief executive officer, Tim Lu, MD, PhD, has been appointed to the Alliance for Regenerative Medicine’s (ARM) 2022 Board of Directors.
-
Senti Bio Awarded Funding from National Cancer Institute (NCI) to Support Development of Logic Gated Allogeneic CAR-NK Cell Therapy SENTI-202 to Treat Acute Myeloid Leukemia
9/28/2021
Senti Bio, a leading gene circuit company, announced that it has been awarded a Small Business Innovation Research contract to support further development of SENTI-202 for acute myeloid leukemia towards clinical development.
-
The collaboration between Spark and NeuExcell increased the hope for Huntington's disease cure in near future. This is going to be a great relief for all the patients.
-
Senti Bio Adds Prominent Scientific and Industry Leaders to its Scientific Advisory Board
8/17/2021
Senti Bio today announced the addition of three independent experts to its Scientific Advisory Board (SAB).
-
Determined to take its next-generation engineered cell therapies to the next level, BlueRock teams up with Senti Biosciences with futuristic medicines in mind.
-
Senti Bio and BlueRock Therapeutics Enter Collaboration to Develop Gene Circuit-Engineered Cell Therapies for Regenerative Medicine
5/26/2021
Collaboration combines BlueRock’s leading induced pluripotent stem cell (iPSC) platform technology and genome biology expertise with Senti Bio’s proprietary gene circuit technology platform, including Smart Sensors and Regulator Dials
-
Senti Bio to Present Data from CAR-NK Cell Oncology Pipeline at ISCT Annual Meeting
5/25/2021
Senti Bio, a leading gene circuit company, announced presentations on its gene circuit engineered allogeneic CAR-NK cell therapy pipeline at the International Society for Cell and Gene Therapy Virtual Annual Meeting.
-
Senti Bio Announces Key Leadership Appointments
5/19/2021
- Deborah Knobelman, PhD, appointed Chief Financial Officer - - Curt Herberts, MBS, promoted to Chief Operating Officer and Philip Lee, PhD, promoted to Chief Technology Officer -
-
Senti Bio to Present Data from CAR-NK Cell Oncology Pipeline at ASGCT 24th Annual Meeting
5/11/2021
Using a Regulator Dial gene circuit, Senti Bio regulated gene expression in preclinical in vivo models via FDA-approved, orally dosed NS3 inhibitors
-
Spark Therapeutics Enters Collaboration with Senti Bio to Bolster Industry-Leading Gene Therapy Research Platform
4/13/2021
Collaboration combines Senti Bio’s leading-edge gene circuit technology platform and high-throughput synthetic promoter design capabilities with Spark Therapeutics’ investigational gene therapies targeting the central nervous system, eye or liver Senti Bio is potentially eligible to receive upfront, opt-in and milestone payments exceeding $645 million
-
Senti Bio Enters Collaboration with Spark Therapeutics to Develop Next-Generation Precision Gene Therapies
4/13/2021
- Collaboration combines Senti Bio’s leading-edge gene circuit technology platform and high-throughput synthetic promoter design capabilities with Spark Therapeutics’ investigational gene therapies targeting the central nervous system, eye or liver -
-
Senti Bio Presents Preclinical Data from CAR-NK Cell Programs at AACR Virtual Annual Meeting
4/12/2021
Senti Bio, a leading gene circuit company, today announced that results from its discovery-stage oncology program using allogeneic CAR-NK cells were presented during a poster session at the American Association for Cancer Research (AACR) Virtual Annual Meeting on April 10, 2021.
-
Senti Bio to Present Data from CAR-NK Cell Oncology Pipeline at Upcoming Scientific Conference
3/12/2021
Senti Bio, a leading gene circuit company, today announced the acceptance of an abstract for presentation at the American Association for Cancer Research (AACR) Virtual Annual Meeting.
-
Senti Bio to Participate in Upcoming Investor Conferences
2/11/2021
- Senti Bio, a leading gene circuit company, today announced that company leadership will participate in two upcoming investor conferences. SVB Leerink 10 th Annual Global Healthcare Conference Date: February 23 rd Event: 1x1 Investor Meetings Barclays Global Healthcare Conference Date: March 9 th Event: Presentation (3:00 p.m. EST) Date: March 11 th Event: 1x1 Investor Meetings